Advanced Bladder Cancer VL

Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar

Details
Beyond Endpoints: An interview with Dr Srikala Sridhar, study chair of the BL12 trial Investigator-initiated trials (IITs) often tackle important questions that are not addressed elsewhere. [transcript] Compared with a pharmaceutical company–managed trials, benefits of IITs include generating data in a real-world setting and resolving issues that confound physicians in daily practice. A recent ope...

Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III

Details
Black individuals with muscle-invasive bladder cancer (MIBC) experience 21% lower odds of guideline-based treatment (GBT). Differences in treatment account for 35% of observed Black-White differences in survival. Samuel Washington III, MD, MAS joins Ashish Kamat, MD, MBBS, to highlight this data published in Cancer Medicine. Low GBT levels demonstrated an "under-allocation" of GBT to those who nee...

Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden

Details
Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...

Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde

Details
Guru Sonpavde joins Alicia Morgans, MD, MPH in a discussion on the treatment landscape of muscle-invasive bladder cancer and several trials that could lead to changes in treatment patterns across the bladder cancer disease spectrum. They review data recently presented at the 2020 European Society for Medical Oncology Virtual Congress, (ESMO) including sacituzumab govitecan in Cohort 3 of the TROPH...

Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar

Details
The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...

ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH highlighting promising data from a different antibody-drug conjugate called sacituzumab govitecan (IMMU-132). There are a number of ongoing studies where sacituzumab govitecan which is being studied in advanced bladder cancer. Enfortumab vedotin targets Nectin-4, while sacituzumab govitecan is targeting Trop-2. Dr. Grivas highlights the final r...

ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks

Details
In this clinical conversation with Alicia Morgans, MD, MPH, and Joshua Meeks, MD, PhD we hear their clinical perspective combination therapies when treating metastatic urothelial carcinoma. They discuss several studies with recent data from the European Society for Medical Oncology Virtual Congress, (ESMO) 2020 including the KEYNOTE-361 the DANUBE trial, and the IMvigor130 data presented at earlie...

Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta

Details
Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...

The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo

Details
Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...

Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas

Details
Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...